https://www.selleckchem.com/products/pfi-2.html
6; 95% CI, 12.2 to 17.2). The cumulative incidence increased up to 20 years after primary diagnosis, reaching 3.4% (95% CI, 2.8% to 4.0%) after 20 years of follow up. The risk of developing a CTGCT decreased with age (hazard ratio [HR], 0.93; 95% CI, 0.90 to 0.96), was lower after nonseminomatous germ cell tumor (HR, 0.58; 95% CI, 0.35 to 0.96) and decreased with every additional cycle of chemotherapy (HR , 0.74; 95% CI, 0.64 to 0.85). Approximately one in every 30 survivors of TGCT will develop a CTGCT, with CTGCT incidence increasing up
Like
Comment
Share
